Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity is increased in Alzheimer disease.
about
Blood-cerebrospinal fluid barrier permeability in Alzheimer's diseaseBiomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomicsUsing neurolipidomics to identify phospholipid mediators of synaptic (dys)function in Alzheimer's Disease.Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease.Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity: a biomarker of blood-cerebrospinal fluid barrier permeability.Phospholipases A2 and neural membrane dynamics: implications for Alzheimer's disease.Inhibition of sPLA₂-IIA prevents LPS-induced neuroinflammation by suppressing ERK1/2-cPLA₂α pathway in mice cerebral cortex.Detection and quantification of microparticles from different cellular lineages using flow cytometry. Evaluation of the impact of secreted phospholipase A2 on microparticle assessmentTargeting NADPH oxidase and phospholipases A2 in Alzheimer's disease.Lipidomics of Alzheimer's disease: current status.Role of cytosolic calcium-dependent phospholipase A2 in Alzheimer's disease pathogenesis.Positive and negative effects of prostaglandins in Alzheimer's disease.Proteome of brain glia: the molecular basis of diverse glial phenotypes.Lipidomics of Alzheimer's disease.Oligomeric amyloid-beta induces MAPK-mediated activation of brain cytosolic and calcium-independent phospholipase A2 in a spatial-specific manner.An integrated metabolomics approach for the research of new cerebrospinal fluid biomarkers of multiple sclerosis.Secreted phospholipase A2-IIA-induced a phenotype of activated microglia in BV-2 cells requires epidermal growth factor receptor transactivation and proHB-EGF shedding.Activity-based targeting of secretory phospholipase A2 enzymes: A fatty-acid-binding-protein assisted approach.Low platelet iPLA₂ activity predicts conversion from mild cognitive impairment to Alzheimer's disease: a 4-year follow-up study.Inhibition of phospholipase A2 in rat brain decreases the levels of total Tau protein.
P2860
Q24631720-69B1E768-15BF-4F1C-ABE5-76E4B58B0ABEQ27024518-F57B9946-FA41-4497-B3D0-F456E8C30BB8Q30451918-68EA380A-EA01-4342-ABA9-7A35D4E5728EQ33712475-3A51C8D9-9A37-43F5-8977-2D756B720B71Q33912628-FF5FE0E6-5BD7-4C77-B004-7132F0061027Q34679377-607B8486-D0CE-4562-9CCE-C2F556CF1301Q35018919-CC688D96-DC0F-483A-9E95-E630F7663F15Q35542696-846EF2EE-9D45-4118-847A-27E492D19659Q37701322-1940782A-E821-49B5-8DB3-E416136DA296Q37980283-19E60C30-6E36-4129-802E-50B0CBDB9789Q38014755-F3E686C5-DF10-4B28-A3C5-D1078C8015DAQ38132922-3C7636BF-1029-4910-986E-1BBEEDCA07A4Q38152439-92DB2379-1237-4A46-AEEB-7DAEAEDE0E0CQ38191024-273E0333-BE45-4B78-831F-B726A670999AQ41149645-0971D9C0-AEE4-493C-B26B-41C5A9504B9BQ41411691-6CE9138A-9513-4D7D-A3AC-F846FF9D78EEQ41508882-979570AA-5468-45AC-B7D2-433C9208909CQ46838226-EE099F8E-FF89-4AA1-8E06-879B3292540FQ49031432-23877929-7D4E-4802-B17F-99B3ABE78182Q53317312-B0615DB1-3C79-45B7-9767-25E0B8AEB0E8
P2860
Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity is increased in Alzheimer disease.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Cerebrospinal fluid secretory ...... ncreased in Alzheimer disease.
@ast
Cerebrospinal fluid secretory ...... ncreased in Alzheimer disease.
@en
type
label
Cerebrospinal fluid secretory ...... ncreased in Alzheimer disease.
@ast
Cerebrospinal fluid secretory ...... ncreased in Alzheimer disease.
@en
prefLabel
Cerebrospinal fluid secretory ...... ncreased in Alzheimer disease.
@ast
Cerebrospinal fluid secretory ...... ncreased in Alzheimer disease.
@en
P2093
P2860
P50
P1433
P1476
Cerebrospinal fluid secretory ...... ncreased in Alzheimer disease.
@en
P2093
Khalid Iqbal
Sonia Chalbot
Tormod Fladby
P2860
P304
P356
10.1373/CLINCHEM.2009.130286
P407
P577
2009-10-22T00:00:00Z